

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Colorectal cancer (CRC)	Heat shock 105 kDa protein 1 (HSPH1; HSP105; HSP110)	Studies in patient samples and in mice identified a mutant form of HSP110 that improved the sensitivity of CRC cells to chemotherapy. In patients with high levels of a mutant form of HSP110 in CRC cells, chemotherapy response and disease-free survival were better than those in patients with low levels of the mutant protein. In cultured CRC cells, overexpression of the mutant protein sensitized tumor cells to oxaliplatin and 5-fluorouracil (5-FU) chemotherapy. Next steps include designing small peptides that mimic the sensitizing function of the mutant HSP110.	Patent application filed; licensing status undisclosed	Dorard, C. <i>et al. Nat. Med.</i> ; published online Sept. 25, 2011; doi:10.1038/nm.2457 <b>Contact:</b> Alex Duval, Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France e-mail: <a href="mailto:alex.duval@inserm.fr">alex.duval@inserm.fr</a> <b>Contact:</b> Carmen Garrido, Institut National de la Santé et de la Recherche Médicale (INSERM), Dijon, France e-mail: <a href="mailto:cgarrido@u-bourgogne.fr">cgarrido@u-bourgogne.fr</a>
<p><b>SciBX 4(39); doi:10.1038/scibx.2011.1086</b>                      Published online Oct. 6, 2011</p>				